Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.48 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.48 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL176001 | 0.82 | NAMPT (0.37) | MAPK1MAPK3MAP2K2MAP2K1MAPK6 | |
| SCHEMBL173496 | 0.80 | MAPK1 (0.55) | MAPK1MAPK3MAP2K2MAP2K1MAPK6 | |
| SCHEMBL12074360 | 0.80 | — | — | |
| SCHEMBL18197045 | 0.79 | GRIN2B (0.35) | — | |
| SCHEMBL15022646 | 0.78 | ROCK2 (0.68) | MAPK1MAPK3MAP2K2MAP2K1MAPK6 | |
| SCHEMBL15021912 | 0.78 | ROCK2 (0.68) | MAPK1MAPK3MAP2K2MAP2K1MAPK6 | |
| SCHEMBL15021797 | 0.77 | ROCK2 (0.66) | MAPK1MAPK3MAP2K2MAP2K1MAPK6 | |
| SCHEMBL18197043 | 0.76 | GRM4 (0.36) | — | |
| SCHEMBL168269 | 0.74 | MAPK1 (0.56) | MAPK1MAPK3MAP2K2MAP2K1MAPK6 | |
| SCHEMBL18197038 | 0.74 | F10 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2613782-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | claimed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | claimed |
| US-20200268897-A1 | Phosphatase Binding Compounds and Methods of Using Same | YALE UNIVERSITY | 2020-08-27 | — | — | US | disclosed |
| EP-2613782-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8946216-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946216-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946216-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| WO-2012030685-A2 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MAPK3, MAPK1, MAP3K1 | MAPK1 2/4885MAPK3 1/4885MAP2K2 58/4885 |
| US-20200268897-A1 | Phosphatase Binding Compounds and Methods of Using Same | PPP5C, PPP4C, DUSP26 | MAPK1 1118/4885MAPK3 748/4885MAP2K2 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.